Skip to main content

Day: March 28, 2023

Adeia Signs Long-Term Semiconductor Patent License Agreement with Western Digital

Agreement includes a license to Adeia’s Hybrid Bonding Portfolio SAN JOSE, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (“Adeia” or the “Company”), the company whose patented innovations enhance billions of devices, today announced that Western Digital (Nasdaq: WDC), a global leader in data storage solutions, entered into a long-term agreement to license Adeia’s semiconductor patent portfolio, including those relating to hybrid bonding. “Western Digital continues to be a leader in the industries it serves with next-generation 3D NAND memory and storage solutions,” said Dana Escobar, chief licensing officer and general manager, semiconductor, at Adeia. “This agreement demonstrates the long-term value proposition offered by Adeia’s intellectual property portfolio to this vital sector...

Continue reading

Adeia Signs Long-Term Semiconductor Patent License Agreement with Kioxia

Agreement includes a license to Adeia’s Hybrid Bonding Portfolio SAN JOSE, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (“Adeia” or the “Company”), the company whose patented innovations enhance billions of devices, today announced that Kioxia Corporation, a world leader in flash memory and solid-state drives, entered into a long-term agreement to license Adeia’s semiconductor patent portfolio, including those relating to hybrid bonding. “Kioxia continues to be a leader in the industries it serves with next-generation 3D NAND memory and storage solutions,” said Dana Escobar, chief licensing officer and general manager, semiconductor, at Adeia. “This agreement demonstrates the long-term value proposition offered by Adeia’s intellectual property portfolio to this vital sector of the...

Continue reading

Azincourt Energy Completes the 2023 Drill Program at the East Preston Uranium Project

Figure 1: East Preston Project Location – Western Athabasca Basin, Saskatchewan, Canada Figure 1: East Preston Project Location – Western Athabasca Basin, Saskatchewan, Canadaimage3 Figure 2: 2023 Target areas and Drill Hole Locations at the East Preston Uranium Project3,066 m completed in 13 drill holes Dravite clay alteration identified in K and H-Zones Over 600 samples sent for analysisVANCOUVER, British Columbia, March 28, 2023 (GLOBE NEWSWIRE) — AZINCOURT ENERGY CORP. (“Azincourt” or the “Company”) (TSX.V: AAZ, OTCQB: AZURF), is pleased to announce that the 2023 exploration program has been completed at the East Preston uranium project in the Athabasca Basin, Saskatchewan, Canada. Drilling for the 2023 program at the East Preston Project commenced on February 2nd and was complete on March 8th. In total 3,066 metres...

Continue reading

Unrivaled Brands Enters Into Binding Debt Settlement Term Sheet Reducing Debt by $3.25M

SANTA ANA, Calif., March 28, 2023 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations throughout California, is pleased to announce it has entered into a binding settlement term sheet to settle an aggregate of $3,250,000 of indebtedness to certain noteholders of the Company. In June 2021, the Company issued four promissory notes in the amount of $4,500,000. The Company and the Noteholders have now agreed to reduce the total amount of principal and interest owed to $1,250,000, payable over 60 months and bearing interest at a rate of 10.0% per annum. Sabas Carrillo, Unrivaled’s Chief Executive Officer commented, “We want to sincerely thank our partners and creditors for continuing to work with us in restructuring our debt.” Additional details...

Continue reading

Neutra’s Strategic Move to Put the Organization in Position to Achieve Its Plans for Growth

KATY, TX, March 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –  Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, last month announced the execution of a letter of intent to acquire Mercury Clinical Research, a privately-owned site management organization (SMO) comprised of a network of physicians conducting clinical trials for top-tier pharmaceutical companies. In preparation for the potential acquisition, the Company has taken the next steps to achieve a successful negotiation.  Neutra Corporation has retired the last of its debt from 2015. Shortly after the company announced that Power Up had completed their Series G Convertible Preferred Shares, the company relied on Power Up to provide funding for the next filing. As of the beginning of the 1st quarter 2023, Power Up has...

Continue reading

High Arctic Announces 2022 Fourth Quarter and Year End Financial and Operating Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, March 28, 2023 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its fourth quarter and year-end results today. The audited consolidated financial statements, management discussion & analysis (“MD&A”), and annual information form for the year ended December 31, 2022 will be available on SEDAR at www.sedar.com, and on High Arctic’s website at www.haes.ca. All amounts are denominated in Canadian dollars (“CAD”), unless otherwise indicated. Mike Maguire, Chief Executive Officer commented: “High Arctic enters 2023 well positioned to increase our service activity in...

Continue reading

Semantix Acquires Health Data Software and Operations to Expand Presence in the Pharma Industry

SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) — Semantix Inc., a leading Latin American end-to-end data and enterprise AI platform provider (“Semantix”), today announced the acquisition of ATSaúde’s assets, businesses, and operations as part of the company’s strategic plan to expand its offerings and presence in the Healthcare & Life Science industry in Brazil, with a specific focus on the pharmaceutical industry. Semantix’s CEO, Leonardo Santos, said, “The pharma industry offers a huge opportunity to expand our business and this acquisition is a significant step towards achieving that goal. It is fully aligned with our product roadmap and we believe that ATSaúde’s products, expertise and knowledge of the pharma industry will be invaluable to us as we continue to develop new products and services.” ATSaúde...

Continue reading

Semantix Announces Fourth Quarter and Full Year 2022 Financial Results

Proprietary SaaS Revenue increases 67% in 4Q22 compared to 4Q21 SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) — Semantix, Inc. (NASDAQ: STIX), a leading Latin American end-to-end data and AI platform provider, today announced its financial results for the fourth quarter and the year ended December 31, 2022. “We believe our positioning at the forefront of emerging data, analytics and AI technologies was reflected in strong Proprietary SaaS revenue growth in the fourth quarter, thus solidifying Proprietary SaaS as a key driver of growth in our business. We plan to accelerate our go-to-market plan with this differentiated offering” said Leonardo Santos, CEO and Founder of Semantix. “We are thrilled with the ongoing innovation in our product portfolio, with newer solutions leveraging data and enabling our customers to develop...

Continue reading

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

– Investigational New Drug (IND) application submitted for lead candidate SNS-101, a conditionally active VISTA-blocking antibody – – New collaborations with Regeneron, the National Cancer Institute and Washington University in St. Louis will support development of SNS-101 – – Company anticipates advancing a second TMAb™ program to IND-enabling studiesfollowing successful candidate selection – – Strong balance sheet with cash runway into the second half of 2025 – BOSTON, March 28, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for full-year 2022 and provided recent business updates. “Over the last year...

Continue reading

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 deletion syndrome $50.6 million in cash and cash equivalents at December 31, 2022; Cash runway to mid-year 2024 DEVON, Pa., March 28, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights and a pipeline update. “We remain focused on enrolling patients in our confirmatory...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.